Business
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Data demonstrate potent suppression of MAPK signaling and viability in KRAS mutant cell lines, as well as anti-tumor activity across multiple KRASG12D and KRASG12V cell-derived xenograft (CDX) modelsBBO-11818’s selectivity for KRAS demonstrated by its >1000-fold lower potency against NRAS, HRAS, and BRAF-mutant cell linesEfficacy of the combination with BBOT’s RAS:PI3K⍺ breaker, BBO-10203, is driven by a robust decrease in tumor cell proliferation and increase in apoptosis; combination benefit a
About this update from Bridgebio Oncology Therapeutics, Inc.
[{"type":"image","alt":"TheRas, Inc. (d/b/a BBOT)","displaySize":"","headline":null,"caption":"TheRas, Inc. (d/b/a BBOT)","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":143,"url":"https://media.zenfs.com/en/globenewswire.com/9479f198b092ba1412cb0ee76f46ca4a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fHlO5lqk7Y3zBP.mSEEEmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9479f198b092ba1412cb0ee76f46ca4a","width":300,"height":143}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Data demonstrate potent suppression of MAPK signaling and viability in KRAS mutant cell lines, as well as anti-tumor activity across multiple KRASG12D and KRASG12V cell-derived xenograft (CDX) models","length":199,"tagName":"p"}]},{"val":[{"type":"text","content":"BBO-11818’s selectivity for KRAS demonstrated by its >1000-fold lower potency against NRAS, HRAS, and BRAF-mutant cell lines","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Efficacy of the combination with BBOT’s RAS:PI3K⍺ breaker, BBO-10203, is driven by a robust decrease in tumor cell proliferation and increase in apoptosis; combination benefit also observed with cetuximab and anti-PD-1 treatment ","length":228,"tagName":"p"}]},{"val":[{"type":"text","content":"BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in patients with KRAS mutant pancreatic, non-small cell lung, and colorectal cancer with initial Phase 1 clinical data expected in the second half of 2026","length":226,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":780,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced new preclinical data on BBO-11818 demonstrating its potential as a potent panKRAS inhibitor targeting mutant KRAS in both the ON (active GTP-bound) and OFF (inactive GDP-bound) states, with selectivity over HRAS and NRAS. The data were presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.","length":565,"tagName":"p"},{"type":"text","content":"“KRAS is one of the most commonly mutated oncogenes in human cancers, and...